

**CENTER FOR DRUG EVALUATION AND RESEARCH**

*APPLICATION NUMBER:*

**50-720/S-006**

**ADMINISTRATIVE DOCUMENTS**  
**AND**  
**CORRESPONDENCE**



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

*Dev. file*

NDA 50-720/S-006

Food and Drug Administration  
Rockville MD 20857

AUG 4 1998

SmithKline Beecham Pharmaceuticals  
One Franklin Plaza  
P.O. Box 7929  
Philadelphia, PA 19101-7929

Attention: Sharon W. Shapowal, R.Ph.  
Associate Director  
U.S. Regulatory Affairs

Dear Ms. Shapowal:

We acknowledge receipt of your supplemental application for the following:

Name of Drug: Augmentin® (amoxicillin/clavulanate potassium)

NDA Number: 50-720

Supplement Number: S-006

Date of Supplement: July 23, 1998


Date of Receipt: July 24, 1998

Unless we find the application not acceptable for filing, this application will be filed under Section 505(b)(1) of the Act on September 22, 1998 in accordance with 21 CFR 314.101(a).

All communications concerning this NDA should be addressed as follows:

Food and Drug Administration  
Division of Anti-Infective Drug Products, HFD-520  
Office of Drug Evaluation IV  
Center for Drug Evaluation and Research  
Attention: Document Control Room  
5600 Fishers Lane  
Rockville, MD 20857

Sincerely,

*for*  James D. Bona, R.Ph., M.P.H.  
Chief, Project Management Staff  
Division of Anti-Infective Drug Products, HFD-520  
Office of Drug Evaluation IV  
Center for Drug Evaluation and Research